-->
Long-term low-dose aspirin does not improve overall cognition in elderly women, although it may reduce the risk of decline in category fluency, according to a report published online April 27 in BMJ.
Jae Hee Kang, ScD, and colleagues from Brigham and Women's Hospital in Boston, randomized 6,377 women at least 65 years old to low-dose aspirin (100 mg every other day) or placebo for a mean of 9.6 years. Cognitive function was assessed by tests for general cognition, verbal memory, and category fluency, a total of three times every 2 years over the telephone.
The researchers found that cognitive function was similar in the two groups at the initial assessment. The mean decline in global cognitive score (average performance across all tests), the risk of substantial cognitive decline and verbal memory were also similar in the two groups. However, the aspirin group had a lower risk of decline in category fluency-in this study, this fluency was tested by asking subjects to name as many animals as possible in 1 minute (RR, 0.80).
Kang JH, Cook N, Manson J. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ. Published online at http:// http://www.bmj.com/cgi/rapidpdf/bmj.39166.597836.BEv1/.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More